Everolimus in advanced/metastatic renal cell carcinoma in adults after sunitinib progression

被引：0
|
作者：
Martin-Vila, A. [1 ]
Alvarez-Payero, M. [1 ]
Martinez-Lopez de Castro, N. [1 ]
Suarez-Santamaria, M. [1 ]
Castro-Dominguez, J. M. [1 ]
Ascunce-Saldana, M. D. P. [1 ]
机构：
[1] Hosp Meixoeiro, Complexo Hosp Univ Vigo, Vigo, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2013年 / 35卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：907 / 907
页数：1
相关论文
共 50 条
  • [11] Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies
    Patel, Shiven B.
    Stenehjem, David D.
    Gill, David M.
    Tantravahi, Srinivas K.
    Agarwal, Archana M.
    Hsu, JoAnne
    Vuong, Winston
    Pal, Sumanta K.
    Agarwal, Neeraj
    CLINICAL GENITOURINARY CANCER, 2016, 14 (02) : 153 - 159
  • [12] Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma
    Herrmann, E.
    Marschner, N.
    Grimm, M. O.
    Ohlmann, C. H.
    Hutzschenreuter, U.
    Overkamp, F.
    Groschek, M.
    Blumenstengel, K.
    Puehse, G.
    Steiner, T.
    WORLD JOURNAL OF UROLOGY, 2011, 29 (03) : 361 - 366
  • [13] Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma
    E. Herrmann
    N. Marschner
    M. O. Grimm
    C. H. Ohlmann
    U. Hutzschenreuter
    F. Overkamp
    M. Groschek
    K. Blumenstengel
    G. Pühse
    T. Steiner
    World Journal of Urology, 2011, 29 : 361 - 366
  • [14] ECONOMIC EVALUATION OF EVEROLIMUS VERSUS SORAFENIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA AFTER FAILURE ON TREATMENT WITH SUNITINIB
    Casciano, R.
    Chulikavit, M.
    Di Lorenzo, G.
    Stern, L.
    Liu, Z.
    Wang, X.
    Garay, C.
    Garrison, L.
    ANNALS OF ONCOLOGY, 2010, 21 : 295 - 296
  • [15] Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma
    Czarnecka, Anna M.
    Sobczuk, Pawel
    Korniluk, Jan
    Spychalska, Marta
    Bogusz, Krzysztof
    Owczarek, Anna
    Brodziak, Anna
    Labochka, Dominika
    Moszczuk, Barbara
    Szczylik, Cezary
    FUTURE ONCOLOGY, 2017, 13 (01) : 31 - 49
  • [16] Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Molina, A. M.
    Feldman, D. R.
    Ginsberg, M. S.
    Fischer, P.
    Trinos, M. J.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [17] Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib
    Zimmermann, Kaja
    Schmittel, Alexander
    Steiner, Ursula
    Asemissen, Anne Marie
    Knoedler, Maren
    Thiel, Eckhard
    Miller, Kurt
    Keilholz, Ulrich
    ONCOLOGY, 2009, 76 (05) : 350 - 354
  • [18] Everolimus In Advanced Renal Cell Carcinoma
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    DRUGS, 2009, 69 (15) : 2115 - 2124
  • [19] Model-based assessment of pharmacokinetic changes of sunitinib, tacrolimus, and everolimus in a patient with metastatic renal cell carcinoma after renal transplantation
    Ito, Takahiro
    Yamamoto, Kazuhiro
    Ogawa, Satoshi
    Furukawa, Junya
    Harada, Kenichi
    Fujisawa, Masato
    Omura, Tomohiro
    Yano, Ikuko
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (05) : 405 - 409
  • [20] Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma
    Rautiola, Juhana
    Utriainen, Tapio
    Peltola, Katriina
    Joensuu, Heikki
    Bono, Petri
    ACTA ONCOLOGICA, 2014, 53 (01) : 113 - 118
12345